UNSPSC 51373469: Guaifenesin/hydromorphone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373469 Guaifenesin/hydromorphone, a Commodity code, encompasses pharmaceutical products and over-the-counter medications that state and local governments purchase for community health, emergency response, and public health initiatives. Recent solicitations show state and local agencies buying naloxone and safe drug deactivation systems for overdose response, along with generic multi-source pharmaceuticals and OTC products distributed through state and local health facilities. Issuing bodies include county health departments, state agencies administering cooperative purchasing programs, and multistate purchasing alliances. The mix reflects both direct county procurement and centralized purchasing vehicles that serve multiple participating jurisdictions.

Seminole County, Florida posted an IFB on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, seeking quarterly deliveries to the Seminole County Community Health Building in Sanford. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for state and local government facilities across participating states including Oregon, with proposals due March 26, 2026 and contract effectiveness anticipated July 1, 2026. Geographic activity spans Florida and Minnesota-led cooperative arrangements, with awards to be distributed through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Vendors responding to MMCAP must comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee on contract purchases.